Should I Buy IMRX? IMRX 2026 Analysis

Should You Buy Immuneering Corp (IMRX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

4.870

1 Day change

-2.60%

52 Week Range

10.080

Analysis Updated At

2026/01/29

Immuneering Corp (IMRX) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock lacks clear positive momentum, and financial performance is weak. While insider buying and analyst optimism provide some positive signals, the overall data does not justify immediate investment.

Technical Analysis

The MACD is slightly positive but contracting, RSI is neutral at 39.692, and moving averages are converging, indicating no strong trend. The stock is trading near its support level of 4.504, but there is no clear bullish signal.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

The low put-call ratios suggest a bullish sentiment in the options market, but the overall volume is low, limiting its significance.

Technical Summary

Sell

Buy

Positive Catalysts

Insiders are buying, with a 266.10% increase in buying activity over the last month. Analysts have an Outperform rating and see potential for the lead drug to generate significant revenues if clinical trials succeed.

Neutral/Negative Catalysts

The stock has been declining, with a -2.60% regular market change and a 40% drop in recent months. Financial performance is weak, with no revenue growth and a significant net loss. No recent news or congress trading data to act as a catalyst.

Financial Performance

In Q3 2025, revenue remained at $0 with no growth. Net income improved slightly by 2.52% YoY but remains deeply negative at -$14,964,875. EPS dropped significantly by -22.45% YoY, reflecting poor financial health.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts rate the stock as Outperform, citing potential blockbuster revenue from its lead drug, atebimetinib. However, they also highlight risks related to the drug's novel mechanism and the need for further trial success.

4 Analyst Rating

Wall Street analysts forecast IMRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMRX is 14.5 USD with a low forecast of 11 USD and a high forecast of 20 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 5.000

Low

Averages

14.5

High

Current: 5.000

Low

Averages

14.5

High

Leerink

Outperform

maintain

$NULL

AI Analysis

2026-01-08

Reason

Leerink

Price Target

$NULL

AI Analysis

2026-01-08

maintain

Outperform

Reason

After Immuneering (IMRX) announced updated overall survival and safety data from its ongoing Phase 2a trial of atebimetinib in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients, Leerink says the updated 12 month data highlights "impressive" 64% landmark OS, which the analyst calls "encouraging." The median progression free survival deteriorated to 8.5 months, which the analyst notes is similar to the 8.5 months shown by Revolution Medicines' (RVMD) daraxonrasib in second-line PDAC, but adds that Immuneering may have a safety advantage that "could facilitate a niche in frailer patients." Leerink has a Outperform rating on Immuneering shares, which are down $3.37, or 40%, to $4.96 in afternoon trading.

Leerink

Outperform

initiated

$15

2025-10-31

Reason

Leerink

Price Target

$15

2025-10-31

initiated

Outperform

Reason

Leerink initiated coverage of Immuneering with an Outperform rating and $15 price target. The firm notes lead asset atebimetinib is an allosteric MEK inhibitor that has shown compelling Phase 2 activity in combination with chemotherapy in first-line pancreatic ductal adenocarcinoma, a tumor type in which over 90% of patients are driven by aberrant, constitutive MAPK signaling. Leerink thinks DCI, which departs from conventional, continuous kinase inhibition and uses high dose, pulsatile blockade, introduces mechanistic risk. However, it sees significant upside if efficacy and tolerability are confirmed in the pivotal trial by allowing a more tolerable approach to MEK inhibition. The firm views atebi as a blockbuster+ agent in PDAC with $2.4B peak revenues, representing $14/share in its model.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for IMRX

Unlock Now

IMRX Should I Buy

IMRX Should I Buy

Should You Buy Immuneering Corp (IMRX) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch